Skip to main content
Erschienen in: Annals of Surgical Oncology 7/2022

17.03.2022 | Hepatobiliary Tumors

Tumor Necrosis Impacts Prognosis of Patients Undergoing Resection for T1 Intrahepatic Cholangiocarcinoma

verfasst von: Diamantis I. Tsilimigras, MD, Aslam Ejaz, MD, MPH, Jordan Cloyd, MD, Alfredo Guglielmi, MD, Luca Aldrighetti, MD, Matthew Weiss, MD, Todd W. Bauer, MD, Sorin Alexandrescu, MD, George A. Poultsides, MD, Shishir K. Maithel, MD, Hugo P. Marques, MD, Guillaume Martel, MD, Carlo Pulitano, MD, Feng Shen, MD, Olivier Soubrane, MD, Bas Groot Koerkamp, MD, Itaru Endo, MD, PhD, Timothy M. Pawlik, MD, MPH, PhD, FACS, FRACS (Hon.)

Erschienen in: Annals of Surgical Oncology | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

The prognostic impact of tumor necrosis among patients undergoing resection for intrahepatic cholangiocarcinoma (ICC) remains ill-defined.

Methods

Patients who underwent curative-intent resection for ICC between 2000 and 2017 were identified using a multi-institutional database. The association of pathologic tumor necrosis with overall survival (OS) and recurrence-free survival (RFS) was examined.

Results

Among 757 patients who underwent resection for ICC, tumor necrosis was present in 384 (50.7%) patients (no necrosis: n = 373, 49.3%; <50% necrosis: n = 291, 38.4%; ≥50% necrosis: n = 93, 12.3%). Tumor necrosis was associated with worse OS (5-year OS: no necrosis 39.3% vs. <50% necrosis 34.7% and ≥50% necrosis 24.0%; p = 0.03) and RFS (5-year RFS: no necrosis 25.7% vs. <50% necrosis 13.9% and ≥50% necrosis 18.8%; p < 0.001). After stratifying by T stage, tumor necrosis was able to further stratify prognosis among patients with T1a ICC (5-year RFS: T1a and no necrosis 46.7% vs. T1a and necrosis 36.1%; p = 0.02), and T1b ICC (5-year RFS: T1b and no necrosis 31.1% vs. T1b and necrosis 11.2%; p = 0.006), but was not associated with outcomes among patients with more advanced T2–T3 disease. Patients with T1a ICC and tumor necrosis had similar 5-year RFS as individuals with T1b ICC and no tumor necrosis (36.1% vs. 31.1%; p = 0.66).

Conclusion

Tumor necrosis was associated with worse prognosis among patients with T1 ICC. Tumor necrosis for T1 ICC should be considered as an important factor to further stratify outcomes of patients with early T-stage ICC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Singal AK, Vauthey JN, Grady JJ, et al. Intra-hepatic cholangiocarcinoma–frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center. J Cancer Res Clin Oncol. 2011;137(7):1071–8.CrossRef Singal AK, Vauthey JN, Grady JJ, et al. Intra-hepatic cholangiocarcinoma–frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center. J Cancer Res Clin Oncol. 2011;137(7):1071–8.CrossRef
2.
Zurück zum Zitat Wu L, Tsilimigras DI, Paredes AZ, et al. Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: facility type is associated with margin status, use of lymphadenectomy and overall survival. World J Surg. 2019;43(7):1777–87.CrossRef Wu L, Tsilimigras DI, Paredes AZ, et al. Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: facility type is associated with margin status, use of lymphadenectomy and overall survival. World J Surg. 2019;43(7):1777–87.CrossRef
3.
Zurück zum Zitat Mavros MN, Economopoulos KP, Alexiou VG, et al. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014;149(6):565–74.CrossRef Mavros MN, Economopoulos KP, Alexiou VG, et al. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014;149(6):565–74.CrossRef
4.
Zurück zum Zitat Spolverato G, Bagante F, Tsilimigras D, et al. Management and outcomes among patients with mixed hepatocholangiocellular carcinoma: a population-based analysis. J Surg Oncol. 2019;119(3):278–87.PubMed Spolverato G, Bagante F, Tsilimigras D, et al. Management and outcomes among patients with mixed hepatocholangiocellular carcinoma: a population-based analysis. J Surg Oncol. 2019;119(3):278–87.PubMed
5.
Zurück zum Zitat de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29(23):3140–5.CrossRef de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29(23):3140–5.CrossRef
6.
Zurück zum Zitat Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84–96.CrossRef Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84–96.CrossRef
7.
Zurück zum Zitat Tsilimigras DI, Sahara K, Wu L, et al. Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches. JAMA Surg. 2020;155(9):823–31.CrossRef Tsilimigras DI, Sahara K, Wu L, et al. Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches. JAMA Surg. 2020;155(9):823–31.CrossRef
8.
Zurück zum Zitat Tsilimigras DI, Hyer JM, Paredes AZ, et al. Tumor burden dictates prognosis among patients undergoing resection of intrahepatic cholangiocarcinoma: a tool to guide post-resection adjuvant chemotherapy? Ann Surg Oncol. 2021;28(4):1970–8.CrossRef Tsilimigras DI, Hyer JM, Paredes AZ, et al. Tumor burden dictates prognosis among patients undergoing resection of intrahepatic cholangiocarcinoma: a tool to guide post-resection adjuvant chemotherapy? Ann Surg Oncol. 2021;28(4):1970–8.CrossRef
9.
Zurück zum Zitat Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.CrossRef Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.CrossRef
10.
Zurück zum Zitat Sasaki K, Margonis GA, Andreatos N, et al. Serum tumor markers enhance the predictive power of the AJCC and LCSGJ staging systems in resectable intrahepatic cholangiocarcinoma. HPB (Oxford). 2018;20(10):956–65.CrossRef Sasaki K, Margonis GA, Andreatos N, et al. Serum tumor markers enhance the predictive power of the AJCC and LCSGJ staging systems in resectable intrahepatic cholangiocarcinoma. HPB (Oxford). 2018;20(10):956–65.CrossRef
11.
Zurück zum Zitat Buettner S, Galjart B, van Vugt JLA, et al. Performance of prognostic scores and staging systems in predicting long-term survival outcomes after surgery for intrahepatic cholangiocarcinoma. J Surg Oncol. 2017;116(8):1085–95.CrossRef Buettner S, Galjart B, van Vugt JLA, et al. Performance of prognostic scores and staging systems in predicting long-term survival outcomes after surgery for intrahepatic cholangiocarcinoma. J Surg Oncol. 2017;116(8):1085–95.CrossRef
12.
Zurück zum Zitat Wei T, Zhang XF, Bagante F, et al. Tumor necrosis impacts prognosis of patients undergoing curative-intent hepatocellular carcinoma. Ann Surg Oncol. 2021;28(2):797–805.CrossRef Wei T, Zhang XF, Bagante F, et al. Tumor necrosis impacts prognosis of patients undergoing curative-intent hepatocellular carcinoma. Ann Surg Oncol. 2021;28(2):797–805.CrossRef
13.
Zurück zum Zitat Gilchrist KW, Gray R, Fowble B, et al. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. J Clin Oncol. 1993;11(10):1929–35.CrossRef Gilchrist KW, Gray R, Fowble B, et al. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. J Clin Oncol. 1993;11(10):1929–35.CrossRef
14.
Zurück zum Zitat Hiraoka N, Ino Y, Sekine S, et al. Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. Br J Cancer. 2010;103(7):1057–65.CrossRef Hiraoka N, Ino Y, Sekine S, et al. Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. Br J Cancer. 2010;103(7):1057–65.CrossRef
15.
Zurück zum Zitat Atanasov G, Dietel C, Feldbrugge L, et al. Tumor necrosis and infiltrating macrophages predict survival after curative resection for cholangiocarcinoma. Oncoimmunology. 2017;6(8):e1331806.CrossRef Atanasov G, Dietel C, Feldbrugge L, et al. Tumor necrosis and infiltrating macrophages predict survival after curative resection for cholangiocarcinoma. Oncoimmunology. 2017;6(8):e1331806.CrossRef
16.
Zurück zum Zitat Tsilimigras DI, Moris D, Mehta R, et al. The systemic immune-inflammation index predicts prognosis in intrahepatic cholangiocarcinoma: an international multi-institutional analysis. HPB (Oxford). 2020;22(12):1667–74.CrossRef Tsilimigras DI, Moris D, Mehta R, et al. The systemic immune-inflammation index predicts prognosis in intrahepatic cholangiocarcinoma: an international multi-institutional analysis. HPB (Oxford). 2020;22(12):1667–74.CrossRef
17.
Zurück zum Zitat Tsilimigras DI, Mehta R, Aldrighetti L, et al. Development and Validation of a Laboratory Risk Score (LabScore) to predict outcomes after resection for intrahepatic cholangiocarcinoma. J Am Coll Surg. 2020;230(4):381–91.CrossRef Tsilimigras DI, Mehta R, Aldrighetti L, et al. Development and Validation of a Laboratory Risk Score (LabScore) to predict outcomes after resection for intrahepatic cholangiocarcinoma. J Am Coll Surg. 2020;230(4):381–91.CrossRef
18.
Zurück zum Zitat Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg. 2005;12(5):351–5.CrossRef Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg. 2005;12(5):351–5.CrossRef
19.
Zurück zum Zitat Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19:716–23.CrossRef Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19:716–23.CrossRef
20.
Zurück zum Zitat Burnham KP, Anderson DR. Multimodel inference understanding AIC and BIC in model selection. Sociol Methods Res. 2004;33:261–304.CrossRef Burnham KP, Anderson DR. Multimodel inference understanding AIC and BIC in model selection. Sociol Methods Res. 2004;33:261–304.CrossRef
21.
Zurück zum Zitat Sengupta S, Lohse CM, Leibovich BC, et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer. 2005;104(3):511–20.CrossRef Sengupta S, Lohse CM, Leibovich BC, et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer. 2005;104(3):511–20.CrossRef
22.
Zurück zum Zitat Richards CH, Roxburgh CS, Anderson JH, et al. Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer. Br J Surg. 2012;99(2):287–94.CrossRef Richards CH, Roxburgh CS, Anderson JH, et al. Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer. Br J Surg. 2012;99(2):287–94.CrossRef
23.
Zurück zum Zitat Bredholt G, Mannelqvist M, Stefansson IM, et al. Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses. Oncotarget. 2015;6(37):39676–91.CrossRef Bredholt G, Mannelqvist M, Stefansson IM, et al. Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses. Oncotarget. 2015;6(37):39676–91.CrossRef
24.
Zurück zum Zitat Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004;4(8):641–8.CrossRef Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004;4(8):641–8.CrossRef
25.
Zurück zum Zitat Tsilimigras DI, Ntanasis-Stathopoulos I, Moris D, et al. Liver tumor microenvironment. Adv Exp Med Biol. 2020;1296:227–41.CrossRef Tsilimigras DI, Ntanasis-Stathopoulos I, Moris D, et al. Liver tumor microenvironment. Adv Exp Med Biol. 2020;1296:227–41.CrossRef
26.
Zurück zum Zitat Martin JD, Seano G, Jain RK. Normalizing function of tumor vessels: progress, opportunities, and challenges. Annu Rev Physiol. 2019;81:505–34.CrossRef Martin JD, Seano G, Jain RK. Normalizing function of tumor vessels: progress, opportunities, and challenges. Annu Rev Physiol. 2019;81:505–34.CrossRef
27.
Zurück zum Zitat Atanasov G, Schierle K, Hau HM, et al. Prognostic significance of tumor necrosis in hilar cholangiocarcinoma. Ann Surg Oncol. 2017;24(2):518–25.CrossRef Atanasov G, Schierle K, Hau HM, et al. Prognostic significance of tumor necrosis in hilar cholangiocarcinoma. Ann Surg Oncol. 2017;24(2):518–25.CrossRef
28.
Zurück zum Zitat Leek RD, Landers RJ, Harris AL, et al. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer. 1999;79(5–6):991–5.CrossRef Leek RD, Landers RJ, Harris AL, et al. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer. 1999;79(5–6):991–5.CrossRef
Metadaten
Titel
Tumor Necrosis Impacts Prognosis of Patients Undergoing Resection for T1 Intrahepatic Cholangiocarcinoma
verfasst von
Diamantis I. Tsilimigras, MD
Aslam Ejaz, MD, MPH
Jordan Cloyd, MD
Alfredo Guglielmi, MD
Luca Aldrighetti, MD
Matthew Weiss, MD
Todd W. Bauer, MD
Sorin Alexandrescu, MD
George A. Poultsides, MD
Shishir K. Maithel, MD
Hugo P. Marques, MD
Guillaume Martel, MD
Carlo Pulitano, MD
Feng Shen, MD
Olivier Soubrane, MD
Bas Groot Koerkamp, MD
Itaru Endo, MD, PhD
Timothy M. Pawlik, MD, MPH, PhD, FACS, FRACS (Hon.)
Publikationsdatum
17.03.2022
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 7/2022
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-11462-y

Weitere Artikel der Ausgabe 7/2022

Annals of Surgical Oncology 7/2022 Zur Ausgabe

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.